Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitis.

Emma Guttman-Yassky Paola FacherisPedro Jesus Gomez-AriasEster Del DucaJoel Correa Da RosaStephan WeidingerRobert BissonnetteApril W ArmstrongJulien SeneschalKilian EyerichYeriel D EstradaSwaroop N BoseDan XuAllshine ChenSvitlana TatulychErman GülerGary ChanKaren M PageUrs Kerkmann

Published in: Allergy (2023)

Alongside improvements in clinical signs and symptoms of AD, 12 weeks of abrocitinib treatment resulted in downregulation of genes associated with inflammation, epidermal hyperplasia, and Th2 and Th22 immune responses in the skin of patients with moderate-to-severe AD.

Keyphrases

wound healing
atopic dermatitis
immune response
high intensity
soft tissue
early onset
oxidative stress
cell proliferation
signaling pathway
toll like receptor
drug induced
sleep quality
gestational age
physical activity
smoking cessation